4 conclusion
In conclusion, acipimox is a well-tolerated lipid-lowering agent that has been increasingly recommended in recent years. Although routine liver function monitoring is not recommended for patients receiving acipimox because hepatotoxicity is rarely caused by the drug, a high degree of vigilance is required of clinicians to diagnose acipimox-induced hepatotoxicity. MgIg is a viable therapeutic option for DILI due to its cytoprotective and immunomodulatory effects.